Losing the Wrong Fat Can Trigger Diabetes

We all hear that excess fat is a health problem, but the flip side is rarely discussed: losing the right kind of fat can be just as dangerous. A team of researchers from the University of Michigan has shown that when healthy adipose tissue breaks down, the body’s metabolic balance can tumble, paving the way for type‑2 diabetes and fatty liver disease.

It sounds paradoxical, right? Too much fat raises the risk of heart disease, insulin resistance and a host of other issues. Yet in rare genetic and autoimmune disorders such as familial partial lipodystrophy type 2 (FPLD2), the body sheds fat in the wrong places, and that loss can be just as harmful. Dr. Elif Oral, a clinician‑scientist who’s spent years chasing this puzzle, says the key lies in what the missing fat actually does for us.

To get to the bottom of the mystery, Oral teamed up with Dr. Ormond MacDougald, graduate student Jessica Maung, and a large collaborative group. They built a mouse model in which the lamin A/C gene—mutated in people with FPLD2—could be turned off only in adipocytes, the cells that make up fat tissue.

The results were striking. Without lamin A/C, fat cells stopped behaving like normal fat cells. Gene‑expression profiles showed a failure to process and store lipids, while the cells themselves became inflamed. Even the mitochondria, the tiny power plants inside the cells, went haywire, producing less energy and more stress signals.

“All of these effects come together to create this perfect environment for the tissue to be really unhealthy and eventually disappear,” Maung explains. In the mouse models—and in tissue samples from patients—the researchers watched adipocytes shrink, die, and vanish, leaving a gap where healthy fat should be.

Why does this matter? Healthy adipose tissue does more than stash calories; it releases hormones that keep blood sugar in check and signals to other organs about the body’s energy status. When that tissue disappears, the liver starts hoarding fat, insulin‑producing beta cells in the pancreas get overworked, and blood sugar spikes. In short, the disease we call type 2 diabetes isn’t just a problem of the pancreas—it’s also a disease of the fat.

“People think of Type 2 diabetes as a disease of beta cells, but it’s actually a disease of fat cells, too,” Oral notes. This perspective opens up fresh therapeutic ideas. Instead of focusing solely on insulin or glucose, future drugs might aim to protect adipocytes, prevent their inflammatory makeover, or even coax them back to life.

The study also underscores the power of collaboration. Clinicians, basic scientists, and patients all played a role, turning a puzzling clinical observation into a mechanistic breakthrough. As MacDougald puts it, “We can’t overstate the importance of the patient population and their involvement.”

In the coming years, researchers hope to translate these insights into treatments that preserve healthy fat, stave off metabolic collapse, and give people with lipodystrophy—or even ordinary obesity—new hope for a healthier future.